人工智慧如何實現醫療事務中更快、更明智的決策：專家問答

人工智慧正在改變醫療事務的決策，提供許多好處和機會。快速處理來自臨床試驗、真實世界證據 (RWE) 和科學文獻的大型數據集。人工智慧可以幫助識別和吸引關鍵意見領袖，優化互動並確保有效溝通。

ChatGPT 等生成式 AI 工具正在改進與醫療專業人員 (HCP) 和患者溝通的書面和視覺內容的創作，從而提高效率和品質。這使得醫療事務部能夠專注於策略任務。

主要問題

• 人工智慧是如何影響協和麒麟的醫療事務決策過程的？
• 人工智慧提升成果和效率的領域範例
• 將人工智慧驅動的洞察融入策略決策的最大課題
• 在您的工作中，AI 如何增強臨床試驗數據和 RWE 的分析？
• 如何確保 AI 產生內容的品質和準確性？
• 特定的人工智慧驅動項目已改善了患者的治療效果
• 將人工智慧引入醫療事務時需要考慮哪些倫理問題？
• 如何解決人工智慧應用中的資料隱私和安全問題？
• 預見人工智慧在醫療事務中的應用會出現哪些趨勢？
• 協和麒麟及其醫療事務部門如何為製藥業的下一波人工智慧創新做好準備

該報告是基於專有產業研究和對產業思想領袖的深入訪談而得出的獨立而簡潔的分析。該報告對製藥業高管需要了解的關鍵趨勢和市場發展進行了深入分析，以應對未來的機會和課題。每份報告的重點都是透過對二手文獻的回顧和已確定的知識差距來確定的。基於這項初步研究，我們將制定基於證據、專家指導的討論指南，以確保研究回答最重要的問題。此外，我們有嚴格的篩選標準，以確保受訪者擁有談論該主題所需的適當經驗、知識和地位。

作為專注於製藥領域的值得信賴的行業領導者，本報告為生物製藥專業人士和決策者提供了深入、可行的見解。我們深厚的行業知識使我們能夠提供相關且有價值的見解，幫助我們的客戶了解新興趨勢並有效地解決複雜的課題。我們的報告以廣泛的研究以及來自領先專家和關鍵意見領袖的獨立、公正的見解為後盾，為您提供所需的準確性和可信度。獨家採訪和數據以及持續的市場監控使我們能夠全面了解市場動態。我們的報告涵蓋 40 多個動態疾病領域、包含 KOL 洞察和定量醫生調查的醫生情報以及行業專家對醫療事務、數位健康、銷售和營銷、市場准入和其他領域問題的看法，使您能夠做出更明智的、數據驅動的決策並在快速變化的行業中保持競爭力。

Transforming decision-making in medical affairs, AI offers numerous benefits and opportunities. Along with rapidly processing large data sets from clinical trials, real-world evidence (RWE) and scientific literature. It helps to identify and engage with key opinion leaders, optimising interactions and ensuring effective dissemination of information.

Generative AI tools like ChatGPT are improving the creation of written and visual content for communication with healthcare professionals (HCPs) and patients, enhancing both efficiency and quality. This allows medical affairs to focus on strategic tasks.

FirstWord spoke with Olivia Kager, medical lead for Kyowa Kirin's German, Austrian and Swiss territories, about how AI is impacting decision-making within the company's medical affairs functions.

Key Questions Answered:

• In what ways has AI started to impact decision-making processes in medical affairs at Kyowa Kirin?
• Can you share examples of areas where AI has improved outcomes or efficiencies?
• What are the biggest challenges in integrating AI-driven insights into strategic decision-making?
• How does AI enhance the analysis of clinical trial data and RWE in your role?
• How do you ensure the quality and accuracy of AI-generated content?
• Can you discuss any specific AI-driven projects that have led to better patient outcomes?
• What ethical considerations do you take into account when implementing AI in medical affairs?
• How do you address concerns about data privacy and security in AI applications?
• What future trends do you foresee in the use of AI in medical affairs?
• How is Kyowa Kirin and its medical affairs function preparing for the next wave of AI innovations in pharma?

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.